Inflammation in multiple sclerosis: The good, the bad, and the complex

Gianvito Martino, Luciano Adorini, Peter Rieckmann, Jan Hillert, Boris Kallmann, Giancarlo Comi, Massimo Filippi

Research output: Contribution to journalArticle

Abstract

Inflammation has always been thought of as detrimental in the pathophysiology of multiple sclerosis (MS). However, emerging genetic data, magnetic-resonance-imaging studies, and immunopathological evidence challenge this simplistic view. The evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in MS, thus explaining some of the results from recent trials of anti-inflammatory agents. We argue that the use of anti-inflammatory drugs to treat MS may not be appropriate in all cases. Precise identification of the inflammatory pathways to be targeted in the different phases of the disease and the timing of such interventions are therefore crucial.

Original languageEnglish
Pages (from-to)499-509
Number of pages11
JournalThe Lancet Neurology
Volume1
Issue number8
DOIs
Publication statusPublished - Aug 1 2002

Fingerprint

Multiple Sclerosis
Inflammation
Anti-Inflammatory Agents
Magnetic Resonance Imaging
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Inflammation in multiple sclerosis : The good, the bad, and the complex. / Martino, Gianvito; Adorini, Luciano; Rieckmann, Peter; Hillert, Jan; Kallmann, Boris; Comi, Giancarlo; Filippi, Massimo.

In: The Lancet Neurology, Vol. 1, No. 8, 01.08.2002, p. 499-509.

Research output: Contribution to journalArticle

Martino, Gianvito ; Adorini, Luciano ; Rieckmann, Peter ; Hillert, Jan ; Kallmann, Boris ; Comi, Giancarlo ; Filippi, Massimo. / Inflammation in multiple sclerosis : The good, the bad, and the complex. In: The Lancet Neurology. 2002 ; Vol. 1, No. 8. pp. 499-509.
@article{88ecd7c595ec4ecc9680ab17a383ce61,
title = "Inflammation in multiple sclerosis: The good, the bad, and the complex",
abstract = "Inflammation has always been thought of as detrimental in the pathophysiology of multiple sclerosis (MS). However, emerging genetic data, magnetic-resonance-imaging studies, and immunopathological evidence challenge this simplistic view. The evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in MS, thus explaining some of the results from recent trials of anti-inflammatory agents. We argue that the use of anti-inflammatory drugs to treat MS may not be appropriate in all cases. Precise identification of the inflammatory pathways to be targeted in the different phases of the disease and the timing of such interventions are therefore crucial.",
author = "Gianvito Martino and Luciano Adorini and Peter Rieckmann and Jan Hillert and Boris Kallmann and Giancarlo Comi and Massimo Filippi",
year = "2002",
month = "8",
day = "1",
doi = "10.1016/S1474-4422(02)00223-5",
language = "English",
volume = "1",
pages = "499--509",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "8",

}

TY - JOUR

T1 - Inflammation in multiple sclerosis

T2 - The good, the bad, and the complex

AU - Martino, Gianvito

AU - Adorini, Luciano

AU - Rieckmann, Peter

AU - Hillert, Jan

AU - Kallmann, Boris

AU - Comi, Giancarlo

AU - Filippi, Massimo

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Inflammation has always been thought of as detrimental in the pathophysiology of multiple sclerosis (MS). However, emerging genetic data, magnetic-resonance-imaging studies, and immunopathological evidence challenge this simplistic view. The evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in MS, thus explaining some of the results from recent trials of anti-inflammatory agents. We argue that the use of anti-inflammatory drugs to treat MS may not be appropriate in all cases. Precise identification of the inflammatory pathways to be targeted in the different phases of the disease and the timing of such interventions are therefore crucial.

AB - Inflammation has always been thought of as detrimental in the pathophysiology of multiple sclerosis (MS). However, emerging genetic data, magnetic-resonance-imaging studies, and immunopathological evidence challenge this simplistic view. The evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in MS, thus explaining some of the results from recent trials of anti-inflammatory agents. We argue that the use of anti-inflammatory drugs to treat MS may not be appropriate in all cases. Precise identification of the inflammatory pathways to be targeted in the different phases of the disease and the timing of such interventions are therefore crucial.

UR - http://www.scopus.com/inward/record.url?scp=0038240048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038240048&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(02)00223-5

DO - 10.1016/S1474-4422(02)00223-5

M3 - Article

C2 - 12849335

AN - SCOPUS:0038240048

VL - 1

SP - 499

EP - 509

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 8

ER -